Skyrizi Cost for Crohn's: Copay Card, Assistance, Real Prices

The published list price for one dose of Skyrizi is $23,838.42, stated as of January 6, 2026, and AbbVie itself adds that this figure may not reflect the price paid by patients (1). Checked 2026-09-30. Working out your real skyrizi cost means understanding which benefit each dose is billed through, what the copay card caps, and whether you are eligible for it at all.

Many of us know the sequence: the biologic is approved, relief arrives, and then an Explanation of Benefits lands that nobody prepared us for. Everything below comes from documents you can open yourself, and it stops where the evidence stops.

Key Takeaways

• The list price is $23,838.42 for one dose of Skyrizi as of January 6, 2026, and AbbVie states this may not be what patients pay (1).
• Your real skyrizi cost is not that figure multiplied out: AbbVie does not say which Skyrizi presentation it covers, so no honest annual total exists.
• Eligible commercially insured patients may pay as little as $0 per treatment with the Skyrizi Complete Savings Card (1)(2).
• For Crohn's and ulcerative colitis, the card caps savings at $1,000 a year toward the infusion and $1,000 a year toward certain monitoring labs (2).
• The card is barred for anyone on Medicare, Medicaid, TRICARE, Department of Defense or Veterans Affairs coverage (1)(2), which rules out many readers.
• No risankizumab biosimilar exists in the US, and Skyrizi was not selected for Medicare price negotiation, so neither force that lowered Stelara's price is coming soon (7)(8).

What Your Skyrizi Cost Looks Like Before Insurance

AbbVie publishes a single list price, the Wholesale Acquisition Cost, of $23,838.42 for one dose of Skyrizi, stated as of January 6, 2026, alongside a note that the WAC may not reflect the price paid by patients (1). Checked 2026-09-30. That number is the starting point insurers negotiate down from, and it matters most if you have no coverage. Insured patients rarely receive it as a bill.

Why one list price does not give you an annual total

This is where most cost articles quietly overreach. AbbVie's page does not state which Skyrizi presentation that price applies to, and Skyrizi comes in several: the prescribing information lists a 600 mg/10 mL single-dose vial for intravenous infusion and a 360 mg/2.4 mL single-dose prefilled cartridge for subcutaneous use, among others (3).

A Crohn's course moves between them. The label, revised 3/2026, gives induction as 600 mg by intravenous infusion over at least one hour at Week 0, Week 4 and Week 8, then maintenance as either 180 mg or 360 mg subcutaneously at Week 12 and every 8 weeks after that (3).

So a first year involves three infusions and roughly six or seven subcutaneous doses, across two product forms and often two billing systems. Multiplying one unattributed list price by the number of doses produces a headline, not information. If you see a confident annual total for Skyrizi, check whether the source says which dose it priced.

The Skyrizi Complete Copay Card: What It Covers and What It Does Not

AbbVie states that eligible commercially insured patients may pay as little as $0 per treatment with the Skyrizi Complete Savings Card (1)(2). That is a real offer, and for many people it removes the drug cost entirely. It is also fenced by limits that surface mid-year, when the card stops paying and nobody can explain why.

The two $1,000 yearly sub-limits most articles miss

For Crohn's disease and ulcerative colitis, the program applies a maximum savings limit of $1,000 per year toward the product-associated infusion, and a separate maximum savings limit of $1,000 per year toward certain lab tests used for monitoring (2).

That is not the drug benefit. Your infusion carries its own charge for the chair, nursing time and observation, billed separately from the medicine. The card helps with that up to $1,000 a year, and with three induction infusions in the first twelve weeks the ceiling can arrive early.

The lab sub-limit exists for a reason written into the label: liver enzymes and bilirubin must be obtained before starting Skyrizi for Crohn's disease, and monitored during treatment (3). That monitoring generates its own bills, and the two caps do not substitute for each other.

Who is shut out of the card

The most common source of confusion deserves stating plainly. The Savings Card is not available to patients receiving reimbursement under any federal, state or government-funded insurance program, including Medicare and Part D, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense and Veterans Affairs programs (1)(2).

This is not an AbbVie quirk: federal anti-kickback rules apply to essentially every branded copay card in the United States. If you are on government coverage, the $0 figure was never available to you.

For enrollment or a coverage check, AbbVie gives 1.866.SKYRIZI (1.866.759.7494), where an Insurance Specialist can review your coverage and possible savings (1).

If You Have No Insurance or Cannot Afford It

AbbVie's own guidance for people who cannot afford Skyrizi is to go to AbbVie.com/PatientAccessSupport, the entry point for its patient assistance program, commonly called myAbbVie Assist (1)(2). Unlike the copay card, it is not limited to commercial insurance.

myAbbVie Assist and AbbVie Patient Access Support

An honest limitation: AbbVie's income-criteria page blocked automated access on the date this was researched, so we will not publish an income threshold or federal poverty level percentage for myAbbVie Assist. Other sites quote figures we cannot verify.

Structurally, programs of this kind generally ask for United States residency, limited or no prescription coverage, demonstrated financial need with income documentation, and an application submitted with your prescriber. Open AbbVie's page for current criteria before assuming you do or do not qualify.

The practical sequence matters more than the paperwork:

1. Ask who in the prescriber's office handles benefits investigations. Most practices treating biologics have someone who does it daily.
2. Apply with your prescriber, not alone. These applications require a clinical section, and incomplete forms are a common cause of delay.
3. Ask about a bridge or free-trial supply while an appeal or application is pending, so paperwork does not interrupt treatment.
4. Treat a denial as a starting point, not an answer. In our community, insurer refusal is more often the real obstacle than price. Our guide to prior authorization and appeals for Crohn's disease walks through the mechanics.

If you are comparing biologics on cost, the same method applied to a different drug appears in our breakdown of Entyvio cost without insurance.

The Medicare Gap: Why Skyrizi Is Harder on Medicare

Medicare patients cannot use the Skyrizi Complete Savings Card at all (1)(2). That exclusion is not a footnote, it is a structural problem, and it deserves more than a line in an eligibility list.

Part B, Part D, and the 2026 numbers

Skyrizi Medicare coverage splits in two. Part B usually covers drugs you would not typically give yourself, such as those given at a doctor's office or hospital outpatient setting, and it covers most injectable and infused drugs when a licensed medical provider gives them, while Part D covers many drugs Part B does not (5).

Because Crohn's induction is an intravenous infusion given by a provider and maintenance is a subcutaneous injection you may administer at home (3), one person can touch both benefits in a year. Asking which benefit each dose runs through is not pedantic, it decides what you pay.

The most useful number here is the annual cap. CMS set the CY 2026 Part D out-of-pocket threshold at $2,100 and the deductible at $615 in its Final CY 2026 Part D Redesign Program Instructions (4). Once that threshold is reached, the enrollee pays no cost sharing for Part D drugs for the rest of the year (4). At this price point it is reached quickly, so the worst exposure is front-loaded rather than endless.

Charitable copay funds are not a reliable backstop

The usual workaround suggested to Medicare patients is a disease-specific charitable copay fund, since these may help where manufacturer cards cannot. Be careful with that advice.

The HealthWell Foundation's Inflammatory Bowel Disease - Medicare Access fund, which is open to Medicare patients only, was listed as Closed, and temporarily closed to new patients due to lack of sufficient funding, when checked on 2026-09-30 (6). These funds reopen and close without notice, so re-check it yourself rather than trusting any article's snapshot, including this one. We will not promise you a grant.

No Biosimilar Is Coming Soon, and No Negotiated Medicare Price Either

Two forces have pushed biologic prices down in the United States recently: biosimilar competition and Medicare price negotiation. Neither is arriving for Skyrizi in the near term.

There is no risankizumab biosimilar on the US market. The candidate CKD-704 was in a Phase 1 pharmacokinetic and immunogenicity study in healthy adults, status recruiting, start date 2025-11-26 (7). Early-phase means years away, not months, and not every candidate reaches approval.

Skyrizi was also not selected for the third cycle of the Medicare Drug Price Negotiation Program. CMS announced the 15 selected drugs on January 27, 2026, with any negotiated prices taking effect beginning in 2028, and Skyrizi does not appear among them. Entyvio does (8).

The contrast with Stelara is instructive. Stelara's cost picture changed because ustekinumab biosimilars launched and because Medicare negotiated a price for it, as we covered in our article on Stelara cost and biosimilars in 2026. For Skyrizi, the levers that exist today are the copay card, patient assistance, site of care and insurance appeals. Still weighing the two drugs clinically? Our head-to-head comparison of Skyrizi and Stelara covers the SEQUENCE trial evidence.

A Practical Checklist for Lowering What You Pay

No single move lowers your Skyrizi cost. What works is a sequence: confirm which benefit each dose is billed through, enroll in the manufacturer program if you are eligible, plan around the Part D cap if you are on Medicare, and appeal in writing. All of this is United States specific.

• Confirm which benefit is billed for each dose, infusion or pharmacy, before the first appointment, and ask for the facility fee separately.
• Enroll in Skyrizi Complete before your first dose if you are commercially insured, and ask specifically about the $1,000 infusion and $1,000 lab monitoring sub-limits (2).
• If you are on Medicare, plan around the $2,100 annual out-of-pocket threshold (4), and ask your plan whether costs can be spread across the year.
• Ask about site of care. An in-office or home infusion versus a hospital outpatient department can change the facility charge substantially. Ask which applies to you rather than assuming one is cheaper.
• Keep every Explanation of Benefits, and appeal denials in writing.
• Re-check every figure. Terms expire, formularies reset in January, and charitable funds open and close. Every number here was checked on 2026-09-30.

Reimbursement and assistance systems differ substantially between countries, so readers elsewhere may find their national IBD organisation or treating centre a better starting point than any US program page.

Frequently Asked Questions

How much does Skyrizi cost without insurance?

AbbVie publishes a list price (Wholesale Acquisition Cost) of $23,838.42 for one dose as of January 6, 2026, and notes it may not reflect what patients pay (1). Because the page does not state which presentation that covers, no honest annual total can be calculated. AbbVie directs uninsured patients to AbbVie.com/PatientAccessSupport (1)(2).

Can I use the Skyrizi copay card if I have Medicare?

No. The card is not available to anyone reimbursed under any federal, state or government-funded program, including Medicare and Part D, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense and Veterans Affairs coverage (1)(2). On Medicare, the relevant protection is the CY 2026 Part D out-of-pocket threshold of $2,100, after which no further cost sharing applies for Part D drugs (4).

Why did my Skyrizi copay card stop covering my infusion?

Usually a sub-limit rather than an error. For Crohn's and ulcerative colitis the program caps savings at $1,000 per year toward the product-associated infusion, and separately at $1,000 per year toward certain monitoring lab tests (2). With three induction infusions in the first twelve weeks (3), the infusion ceiling can be reached early.

Is there a Skyrizi biosimilar that would cost less?

Not in the United States. The risankizumab biosimilar candidate CKD-704 was in a Phase 1 study in healthy adults, recruiting, start date 2025-11-26 (7). Phase 1 is early, so price competition is years away, and no candidate is guaranteed approval.

Will Medicare negotiate a lower Skyrizi price?

Not in the current cycles. CMS announced the 15 drugs selected for the third negotiation cycle on January 27, 2026, with prices effective beginning in 2028, and Skyrizi is not among them, though Entyvio is (8). Later cycles remain possible, but nothing is scheduled.

References

1. AbbVie. Cost and Savings - SKYRIZI (risankizumab-rzaa) for Crohn's Disease. 2026. Checked 2026-09-30. Read the cost and savings page
2. AbbVie. Ways to Save on SKYRIZI (risankizumab-rzaa) for CD and UC. 2026. Checked 2026-09-30. Read the program terms
3. US Food and Drug Administration. SKYRIZI (risankizumab-rzaa) injection, Highlights of Prescribing Information, revised 3/2026. 2026. Checked 2026-09-30. Read the prescribing information
4. Centers for Medicare and Medicaid Services. Final CY 2026 Part D Redesign Program Instructions. 2025. Checked 2026-09-30. Read the instructions
5. Centers for Medicare and Medicaid Services. Prescription Drugs (Outpatient) Coverage. 2026. Checked 2026-09-30. Read the Medicare coverage page
6. HealthWell Foundation. Inflammatory Bowel Disease - Medicare Access Fund. 2026. Checked 2026-09-30. View the fund status
7. ClinicalTrials.gov. Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi, and US-licensed Skyrizi in Healthy Adult Participants. 2025. Checked 2026-09-30. View the study record
8. Centers for Medicare and Medicaid Services. CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation (Fact Sheet). 2026. Checked 2026-09-30. Read the fact sheet